Dysregulated corticostriatal activity in open-field behavior and the head-twitch response induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine

Claudia Rangel-Barajas, Ana María Estrada-Sánchez, Scott J. Barton, Robert T. Luedtke, George V. Rebec

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The substituted amphetamine, 2,5-dimethoxy-4-iodoamphetamine (DOI), is a hallucinogen that has been used to model a variety of psychiatric conditions. Here, we studied the effect of DOI on neural activity recorded simultaneously in the primary motor cortex (M1) and dorsal striatum of freely behaving FvB/N mice. DOI significantly decreased the firing rate of individually isolated neurons in M1 and dorsal striatum relative to pre-drug baseline. It also induced a bursting pattern of activity by increasing both the number of spikes within a burst and burst duration. In addition, DOI increased coincident firing between simultaneously recorded neuron pairs within the striatum and between M1 and dorsal striatum. Local field potential (LFP) activity also increased in coherence between M1 and dorsal striatum after DOI in the low frequency gamma band (30–50 Hz), while corticostriatal coherence in delta, theta, alpha, and beta activity decreased. We also assessed corticostriatal LFP activity in relation to the DOI-induced head-twitch response (HTR), a readily identifiable behavior used to assess potential treatments for the conditions it models. The HTR was associated with increased delta and decreased theta power in both M1 and dorsal striatum. Together, our results suggest that DOI dysregulates corticostriatal communication and that the HTR is associated with this dysregulation.

Original languageEnglish
Pages (from-to)502-510
Number of pages9
JournalNeuropharmacology
Volume113
DOIs
StatePublished - 1 Feb 2017

Fingerprint

Hallucinogens
Head
Neurons
Motor Cortex
Amphetamine
4-iodoamphetamine
Psychiatry
Communication
Pharmaceutical Preparations

Keywords

  • 5-HT serotonin receptor
  • DOI
  • Head-twitch response
  • In vivo electrophysiology

Cite this

Rangel-Barajas, Claudia ; Estrada-Sánchez, Ana María ; Barton, Scott J. ; Luedtke, Robert T. ; Rebec, George V. / Dysregulated corticostriatal activity in open-field behavior and the head-twitch response induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine. In: Neuropharmacology. 2017 ; Vol. 113. pp. 502-510.
@article{ab8f1713858c4e328c2e676e444b7bbb,
title = "Dysregulated corticostriatal activity in open-field behavior and the head-twitch response induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine",
abstract = "The substituted amphetamine, 2,5-dimethoxy-4-iodoamphetamine (DOI), is a hallucinogen that has been used to model a variety of psychiatric conditions. Here, we studied the effect of DOI on neural activity recorded simultaneously in the primary motor cortex (M1) and dorsal striatum of freely behaving FvB/N mice. DOI significantly decreased the firing rate of individually isolated neurons in M1 and dorsal striatum relative to pre-drug baseline. It also induced a bursting pattern of activity by increasing both the number of spikes within a burst and burst duration. In addition, DOI increased coincident firing between simultaneously recorded neuron pairs within the striatum and between M1 and dorsal striatum. Local field potential (LFP) activity also increased in coherence between M1 and dorsal striatum after DOI in the low frequency gamma band (30–50 Hz), while corticostriatal coherence in delta, theta, alpha, and beta activity decreased. We also assessed corticostriatal LFP activity in relation to the DOI-induced head-twitch response (HTR), a readily identifiable behavior used to assess potential treatments for the conditions it models. The HTR was associated with increased delta and decreased theta power in both M1 and dorsal striatum. Together, our results suggest that DOI dysregulates corticostriatal communication and that the HTR is associated with this dysregulation.",
keywords = "5-HT serotonin receptor, DOI, Head-twitch response, In vivo electrophysiology",
author = "Claudia Rangel-Barajas and Estrada-S{\'a}nchez, {Ana Mar{\'i}a} and Barton, {Scott J.} and Luedtke, {Robert T.} and Rebec, {George V.}",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.neuropharm.2016.11.001",
language = "English",
volume = "113",
pages = "502--510",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Ltd",

}

Dysregulated corticostriatal activity in open-field behavior and the head-twitch response induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine. / Rangel-Barajas, Claudia; Estrada-Sánchez, Ana María; Barton, Scott J.; Luedtke, Robert T.; Rebec, George V.

In: Neuropharmacology, Vol. 113, 01.02.2017, p. 502-510.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Dysregulated corticostriatal activity in open-field behavior and the head-twitch response induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine

AU - Rangel-Barajas, Claudia

AU - Estrada-Sánchez, Ana María

AU - Barton, Scott J.

AU - Luedtke, Robert T.

AU - Rebec, George V.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - The substituted amphetamine, 2,5-dimethoxy-4-iodoamphetamine (DOI), is a hallucinogen that has been used to model a variety of psychiatric conditions. Here, we studied the effect of DOI on neural activity recorded simultaneously in the primary motor cortex (M1) and dorsal striatum of freely behaving FvB/N mice. DOI significantly decreased the firing rate of individually isolated neurons in M1 and dorsal striatum relative to pre-drug baseline. It also induced a bursting pattern of activity by increasing both the number of spikes within a burst and burst duration. In addition, DOI increased coincident firing between simultaneously recorded neuron pairs within the striatum and between M1 and dorsal striatum. Local field potential (LFP) activity also increased in coherence between M1 and dorsal striatum after DOI in the low frequency gamma band (30–50 Hz), while corticostriatal coherence in delta, theta, alpha, and beta activity decreased. We also assessed corticostriatal LFP activity in relation to the DOI-induced head-twitch response (HTR), a readily identifiable behavior used to assess potential treatments for the conditions it models. The HTR was associated with increased delta and decreased theta power in both M1 and dorsal striatum. Together, our results suggest that DOI dysregulates corticostriatal communication and that the HTR is associated with this dysregulation.

AB - The substituted amphetamine, 2,5-dimethoxy-4-iodoamphetamine (DOI), is a hallucinogen that has been used to model a variety of psychiatric conditions. Here, we studied the effect of DOI on neural activity recorded simultaneously in the primary motor cortex (M1) and dorsal striatum of freely behaving FvB/N mice. DOI significantly decreased the firing rate of individually isolated neurons in M1 and dorsal striatum relative to pre-drug baseline. It also induced a bursting pattern of activity by increasing both the number of spikes within a burst and burst duration. In addition, DOI increased coincident firing between simultaneously recorded neuron pairs within the striatum and between M1 and dorsal striatum. Local field potential (LFP) activity also increased in coherence between M1 and dorsal striatum after DOI in the low frequency gamma band (30–50 Hz), while corticostriatal coherence in delta, theta, alpha, and beta activity decreased. We also assessed corticostriatal LFP activity in relation to the DOI-induced head-twitch response (HTR), a readily identifiable behavior used to assess potential treatments for the conditions it models. The HTR was associated with increased delta and decreased theta power in both M1 and dorsal striatum. Together, our results suggest that DOI dysregulates corticostriatal communication and that the HTR is associated with this dysregulation.

KW - 5-HT serotonin receptor

KW - DOI

KW - Head-twitch response

KW - In vivo electrophysiology

UR - http://www.scopus.com/inward/record.url?scp=84994494254&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2016.11.001

DO - 10.1016/j.neuropharm.2016.11.001

M3 - Article

VL - 113

SP - 502

EP - 510

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

ER -